Share Price and Basic Stock Data
Last Updated: January 15, 2026, 3:59 am
| PEG Ratio | -5.55 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Cohance Lifesciences Ltd operates in the pharmaceuticals sector and has exhibited notable revenue trends over the past few years. The company reported total sales of ₹1,340 Cr for the fiscal year ending March 2023, reflecting a modest increase from ₹1,320 Cr in the previous year. However, the revenue dipped to ₹1,051 Cr for FY 2024, indicating a decline in demand or operational challenges. In contrast, the trailing twelve months (TTM) sales surged to ₹2,252 Cr, demonstrating a recovery trajectory with strong quarterly performances, particularly in the March 2025 quarter, where sales reached ₹840 Cr. The quarterly sales data reveals fluctuations, with the highest quarterly sales recorded at ₹604 Cr in September 2024 and a low of ₹220 Cr in December 2023. This volatility underscores the company’s need to stabilize its revenue streams and manage market conditions effectively.
Profitability and Efficiency Metrics
The profitability metrics of Cohance Lifesciences Ltd reveal a mixed performance. The company reported a net profit of ₹313 Cr for the TTM, which declined from ₹411 Cr in FY 2023 to ₹300 Cr in FY 2024. The operating profit margin (OPM) stood at 26% for FY 2025, a significant decrease from 43% in FY 2023, indicating rising operational costs or pricing pressures. The interest coverage ratio of 35.12x showcases a strong ability to meet interest obligations, reflecting financial prudence. Additionally, the return on equity (ROE) was recorded at 12.7%, while return on capital employed (ROCE) stood at 14.9%, suggesting that the company is generating reasonable returns relative to its equity and capital investments. However, the declining OPM and net profit margins raise concerns about the sustainability of profitability amidst fluctuating sales and rising costs.
Balance Sheet Strength and Financial Ratios
Cohance Lifesciences Ltd’s balance sheet exhibits a solid capital structure, with total assets reported at ₹5,568 Cr and total liabilities at ₹3,031 Cr as of September 2025. The company’s reserves increased significantly to ₹3,749 Cr, indicating a robust retention of earnings, which is essential for funding future growth. Borrowings stood at ₹451 Cr, reflecting a low debt level relative to equity, with a total debt-to-equity ratio of 0.04, highlighting a conservative financing approach. The current ratio of 2.43x indicates strong liquidity, allowing the company to cover its short-term obligations comfortably. However, the price-to-book value (P/BV) ratio of 17.40x is significantly high compared to typical sector ranges, suggesting that the stock may be overvalued relative to its book value. This could pose a risk to investors if market sentiment shifts.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Cohance Lifesciences Ltd reflects a diverse ownership structure, with promoters holding 57.49% of the equity as of September 2025, a decrease from 60% earlier in the fiscal year. Foreign institutional investors (FIIs) own 6.51%, while domestic institutional investors (DIIs) hold 20.81%. The public shareholding stands at 15.16%, indicating a stable base of retail investors. The declining promoter stake may raise concerns regarding management confidence in the company’s direction. However, the increase in DII holdings suggests growing institutional interest, which can bolster investor confidence. The total number of shareholders was reported at 75,284, indicating a healthy level of public participation. This diverse ownership base can provide resilience against market volatility but may also lead to differing opinions on corporate governance and strategy.
Outlook, Risks, and Final Insight
Cohance Lifesciences Ltd faces a mixed outlook characterized by both opportunities and risks. The company’s strong TTM sales growth indicates potential recovery, yet the decline in profitability margins raises concerns about operational efficiency. Key strengths include a solid balance sheet with low debt levels and strong liquidity, which can support future growth initiatives. However, risks such as fluctuating sales, declining profitability metrics, and a high P/BV ratio could challenge investor sentiment. The company must focus on stabilizing its revenue and improving operational efficiencies to enhance profitability. The evolving regulatory landscape in the pharmaceutical sector could also impact operational dynamics. In a scenario where demand stabilizes and cost pressures ease, Cohance could rebound strongly, but failure to address ongoing challenges may lead to further volatility in performance.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 130 Cr. | 103 | 208/84.3 | 28.7 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,079 Cr. | 374 | 479/192 | 84.5 | 24.3 | 0.18 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.3 Cr. | 44.8 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.4 Cr. | 39.9 | 41.0/17.0 | 139 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,219.38 Cr | 1,122.28 | 52.68 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 278 | 354 | 369 | 348 | 231 | 220 | 253 | 488 | 604 | 307 | 840 | 549 | 556 |
| Expenses | 179 | 207 | 198 | 181 | 133 | 154 | 180 | 363 | 398 | 189 | 611 | 437 | 435 |
| Operating Profit | 100 | 147 | 172 | 167 | 98 | 66 | 73 | 125 | 205 | 118 | 229 | 112 | 121 |
| OPM % | 36% | 41% | 47% | 48% | 42% | 30% | 29% | 26% | 34% | 38% | 27% | 20% | 22% |
| Other Income | 11 | 13 | 11 | 11 | 20 | 14 | 17 | 19 | 16 | 16 | -4 | 6 | 16 |
| Interest | 0 | 1 | 5 | 1 | 0 | 2 | 2 | 10 | 10 | 3 | 10 | 10 | 9 |
| Depreciation | 12 | 12 | 12 | 13 | 12 | 13 | 17 | 31 | 38 | 20 | 54 | 45 | 44 |
| Profit before tax | 98 | 146 | 166 | 164 | 105 | 65 | 71 | 103 | 174 | 110 | 161 | 63 | 84 |
| Tax % | 27% | 26% | 25% | 26% | 25% | 29% | 25% | 27% | 21% | 24% | 27% | 26% | 21% |
| Net Profit | 72 | 108 | 124 | 121 | 80 | 47 | 53 | 75 | 138 | 83 | 117 | 46 | 66 |
| EPS in Rs | 2.83 | 4.23 | 4.87 | 4.74 | 3.13 | 1.84 | 2.10 | 2.96 | 5.44 | 3.26 | 4.73 | 1.28 | 1.94 |
Last Updated: December 28, 2025, 11:04 pm
Below is a detailed analysis of the quarterly data for Cohance Lifesciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 556.00 Cr.. The value appears strong and on an upward trend. It has increased from 549.00 Cr. (Jun 2025) to 556.00 Cr., marking an increase of 7.00 Cr..
- For Expenses, as of Sep 2025, the value is 435.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 437.00 Cr. (Jun 2025) to 435.00 Cr., marking a decrease of 2.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 121.00 Cr.. The value appears strong and on an upward trend. It has increased from 112.00 Cr. (Jun 2025) to 121.00 Cr., marking an increase of 9.00 Cr..
- For OPM %, as of Sep 2025, the value is 22.00%. The value appears strong and on an upward trend. It has increased from 20.00% (Jun 2025) to 22.00%, marking an increase of 2.00%.
- For Other Income, as of Sep 2025, the value is 16.00 Cr.. The value appears strong and on an upward trend. It has increased from 6.00 Cr. (Jun 2025) to 16.00 Cr., marking an increase of 10.00 Cr..
- For Interest, as of Sep 2025, the value is 9.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 10.00 Cr. (Jun 2025) to 9.00 Cr., marking a decrease of 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 44.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 45.00 Cr. (Jun 2025) to 44.00 Cr., marking a decrease of 1.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 84.00 Cr.. The value appears strong and on an upward trend. It has increased from 63.00 Cr. (Jun 2025) to 84.00 Cr., marking an increase of 21.00 Cr..
- For Tax %, as of Sep 2025, the value is 21.00%. The value appears to be improving (decreasing) as expected. It has decreased from 26.00% (Jun 2025) to 21.00%, marking a decrease of 5.00%.
- For Net Profit, as of Sep 2025, the value is 66.00 Cr.. The value appears strong and on an upward trend. It has increased from 46.00 Cr. (Jun 2025) to 66.00 Cr., marking an increase of 20.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 1.94. The value appears strong and on an upward trend. It has increased from 1.28 (Jun 2025) to 1.94, marking an increase of 0.66.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:33 am
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 378 | 834 | 1,010 | 1,320 | 1,340 | 1,051 | 1,198 | 2,252 |
| Expenses | 206 | 449 | 567 | 738 | 766 | 645 | 822 | 1,673 |
| Operating Profit | 172 | 385 | 443 | 582 | 574 | 406 | 375 | 580 |
| OPM % | 45% | 46% | 44% | 44% | 43% | 39% | 31% | 26% |
| Other Income | 1 | 66 | 68 | 133 | 46 | 62 | 58 | 34 |
| Interest | 3 | 23 | 12 | 9 | 13 | 7 | 12 | 33 |
| Depreciation | 12 | 24 | 32 | 39 | 48 | 55 | 77 | 164 |
| Profit before tax | 158 | 405 | 468 | 668 | 560 | 406 | 344 | 417 |
| Tax % | 31% | 22% | 23% | 32% | 27% | 26% | 23% | |
| Net Profit | 109 | 317 | 362 | 454 | 411 | 300 | 265 | 313 |
| EPS in Rs | 12.45 | 14.23 | 17.83 | 16.16 | 11.80 | 10.52 | 11.21 | |
| Dividend Payout % | 0% | 20% | 14% | 28% | 37% | 0% | 0% |
YoY Net Profit Growth
| Year | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 190.83% | 14.20% | 25.41% | -9.47% | -27.01% | -11.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | -176.63% | 11.22% | -34.89% | -17.54% | 15.34% |
Cohance Lifesciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 6 years from 2019-2020 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 8% |
| 3 Years: | -3% |
| TTM: | 64% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -5% |
| 3 Years: | -16% |
| TTM: | 38% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 22% |
| 3 Years: | 23% |
| 1 Year: | -22% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 21% |
| 3 Years: | 17% |
| Last Year: | 13% |
Last Updated: September 5, 2025, 1:41 pm
Balance Sheet
Last Updated: January 7, 2026, 4:29 pm
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | -0.00 | 13 | 25 | 25 | 25 | 25 | 25 | 38 |
| Reserves | 578 | 832 | 1,155 | 1,502 | 1,710 | 2,025 | 1,671 | 3,749 |
| Borrowings | 83 | 186 | 143 | 97 | 70 | 65 | 279 | 451 |
| Other Liabilities | 123 | 142 | 151 | 205 | 160 | 138 | 1,056 | 1,330 |
| Total Liabilities | 783 | 1,173 | 1,474 | 1,830 | 1,966 | 2,254 | 3,031 | 5,568 |
| Fixed Assets | 271 | 357 | 441 | 534 | 663 | 670 | 1,713 | 3,116 |
| CWIP | 111 | 102 | 96 | 30 | 165 | 179 | 256 | 357 |
| Investments | 7 | 338 | 542 | 598 | 536 | 904 | 337 | 454 |
| Other Assets | 394 | 376 | 395 | 667 | 601 | 501 | 725 | 1,641 |
| Total Assets | 783 | 1,173 | 1,474 | 1,830 | 1,966 | 2,254 | 3,031 | 5,568 |
Below is a detailed analysis of the balance sheet data for Cohance Lifesciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 38.00 Cr.. The value appears strong and on an upward trend. It has increased from 25.00 Cr. (Mar 2025) to 38.00 Cr., marking an increase of 13.00 Cr..
- For Reserves, as of Sep 2025, the value is 3,749.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,671.00 Cr. (Mar 2025) to 3,749.00 Cr., marking an increase of 2,078.00 Cr..
- For Borrowings, as of Sep 2025, the value is 451.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 279.00 Cr. (Mar 2025) to 451.00 Cr., marking an increase of 172.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1,330.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,056.00 Cr. (Mar 2025) to 1,330.00 Cr., marking an increase of 274.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 5,568.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,031.00 Cr. (Mar 2025) to 5,568.00 Cr., marking an increase of 2,537.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 3,116.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,713.00 Cr. (Mar 2025) to 3,116.00 Cr., marking an increase of 1,403.00 Cr..
- For CWIP, as of Sep 2025, the value is 357.00 Cr.. The value appears strong and on an upward trend. It has increased from 256.00 Cr. (Mar 2025) to 357.00 Cr., marking an increase of 101.00 Cr..
- For Investments, as of Sep 2025, the value is 454.00 Cr.. The value appears strong and on an upward trend. It has increased from 337.00 Cr. (Mar 2025) to 454.00 Cr., marking an increase of 117.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,641.00 Cr.. The value appears strong and on an upward trend. It has increased from 725.00 Cr. (Mar 2025) to 1,641.00 Cr., marking an increase of 916.00 Cr..
- For Total Assets, as of Sep 2025, the value is 5,568.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,031.00 Cr. (Mar 2025) to 5,568.00 Cr., marking an increase of 2,537.00 Cr..
Notably, the Reserves (3,749.00 Cr.) exceed the Borrowings (451.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Free Cash Flow | 89.00 | 199.00 | 300.00 | 485.00 | 504.00 | 341.00 | 96.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 142 | 51 | 37 | 65 | 30 | 46 | 87 |
| Inventory Days | 556 | 278 | 243 | 259 | 279 | 268 | 199 |
| Days Payable | 190 | 113 | 100 | 97 | 63 | 49 | 96 |
| Cash Conversion Cycle | 509 | 217 | 180 | 228 | 247 | 265 | 190 |
| Working Capital Days | 205 | 64 | 56 | 108 | 99 | 108 | 74 |
| ROCE % | 50% | 40% | 41% | 32% | 19% | 15% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Flexi Cap Fund | 4,000,000 | 0.24 | 225.76 | N/A | N/A | N/A |
| Invesco India Contra Fund | 3,598,511 | 0.99 | 203.1 | 3,323,946 | 2025-12-15 01:49:31 | 8.26% |
| HDFC Balanced Advantage Fund | 3,353,052 | 0.18 | 189.25 | 2,500,285 | 2025-12-15 01:49:31 | 34.11% |
| DSP ELSS Tax Saver Fund | 3,285,254 | 1.06 | 185.42 | 1,910,066 | 2025-12-07 02:39:30 | 72% |
| ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund | 3,068,016 | 2.68 | 173.16 | N/A | N/A | N/A |
| DSP Healthcare Fund | 2,967,600 | 5.27 | 167.49 | 2,489,539 | 2025-12-07 02:39:30 | 19.2% |
| DSP Large & Mid Cap Fund | 2,762,648 | 0.91 | 155.92 | N/A | N/A | N/A |
| Axis Small Cap Fund | 2,540,619 | 0.54 | 143.39 | 2,026,449 | 2025-12-07 02:39:30 | 25.37% |
| DSP Flexi Cap Fund | 2,453,891 | 1.12 | 138.5 | 1,830,535 | 2025-12-07 02:39:30 | 34.05% |
| Canara Robeco Small Cap Fund | 2,261,293 | 0.98 | 127.63 | 1,574,180 | 2025-12-07 02:39:30 | 43.65% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 10.52 | 11.80 | 16.16 | 17.83 | 14.23 |
| Diluted EPS (Rs.) | 10.45 | 11.80 | 16.16 | 17.83 | 14.23 |
| Cash EPS (Rs.) | 13.44 | 13.94 | 18.03 | 17.75 | 13.37 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 66.64 | 80.56 | 68.16 | 59.99 | 46.39 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 66.64 | 80.56 | 68.16 | 59.99 | 46.39 |
| Revenue From Operations / Share (Rs.) | 47.04 | 41.30 | 52.65 | 51.86 | 39.66 |
| PBDIT / Share (Rs.) | 17.04 | 18.37 | 24.08 | 26.39 | 17.86 |
| PBIT / Share (Rs.) | 13.99 | 16.23 | 22.20 | 24.85 | 16.62 |
| PBT / Share (Rs.) | 13.51 | 15.94 | 21.99 | 24.61 | 16.26 |
| Net Profit / Share (Rs.) | 10.40 | 11.80 | 16.16 | 16.21 | 12.12 |
| NP After MI And SOA / Share (Rs.) | 10.52 | 11.80 | 16.16 | 17.83 | 14.23 |
| PBDIT Margin (%) | 36.21 | 44.48 | 45.72 | 50.88 | 45.03 |
| PBIT Margin (%) | 29.74 | 39.29 | 42.16 | 47.92 | 41.90 |
| PBT Margin (%) | 28.71 | 38.58 | 41.76 | 47.45 | 40.99 |
| Net Profit Margin (%) | 22.10 | 28.56 | 30.68 | 31.25 | 30.56 |
| NP After MI And SOA Margin (%) | 22.36 | 28.56 | 30.68 | 34.37 | 35.88 |
| Return on Networth / Equity (%) | 15.78 | 14.64 | 23.70 | 29.71 | 30.68 |
| Return on Capital Employeed (%) | 13.36 | 19.24 | 31.27 | 39.07 | 33.71 |
| Return On Assets (%) | 8.83 | 13.32 | 20.92 | 24.80 | 24.57 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.01 | 0.03 |
| Total Debt / Equity (X) | 0.04 | 0.01 | 0.04 | 0.06 | 0.11 |
| Asset Turnover Ratio (%) | 0.45 | 0.49 | 0.70 | 0.80 | 0.79 |
| Current Ratio (X) | 2.43 | 11.82 | 6.37 | 5.36 | 2.57 |
| Quick Ratio (X) | 1.98 | 9.65 | 4.40 | 4.02 | 1.66 |
| Inventory Turnover Ratio (X) | 6.02 | 3.87 | 1.44 | 1.90 | 1.65 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 49.51 | 22.43 | 7.02 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 44.36 | 20.65 | 6.46 |
| Earning Retention Ratio (%) | 0.00 | 0.00 | 50.49 | 77.57 | 92.98 |
| Cash Earning Retention Ratio (%) | 0.00 | 0.00 | 55.64 | 79.35 | 93.54 |
| Interest Coverage Ratio (X) | 35.12 | 62.77 | 112.74 | 107.82 | 49.73 |
| Interest Coverage Ratio (Post Tax) (X) | 22.44 | 41.30 | 76.66 | 67.23 | 34.75 |
| Enterprise Value (Cr.) | 29662.03 | 17211.94 | 12039.36 | 15779.11 | 12742.73 |
| EV / Net Operating Revenue (X) | 24.77 | 16.37 | 8.98 | 11.95 | 12.62 |
| EV / EBITDA (X) | 68.38 | 36.80 | 19.64 | 23.49 | 28.02 |
| MarketCap / Net Operating Revenue (X) | 24.66 | 16.38 | 8.98 | 11.92 | 12.49 |
| Retention Ratios (%) | 0.00 | 0.00 | 50.48 | 77.56 | 92.97 |
| Price / BV (X) | 17.40 | 8.40 | 6.93 | 10.30 | 10.68 |
| Price / Net Operating Revenue (X) | 24.66 | 16.38 | 8.98 | 11.92 | 12.49 |
| EarningsYield | 0.01 | 0.01 | 0.03 | 0.02 | 0.02 |
After reviewing the key financial ratios for Cohance Lifesciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 10.52. This value is within the healthy range. It has decreased from 11.80 (Mar 24) to 10.52, marking a decrease of 1.28.
- For Diluted EPS (Rs.), as of Mar 25, the value is 10.45. This value is within the healthy range. It has decreased from 11.80 (Mar 24) to 10.45, marking a decrease of 1.35.
- For Cash EPS (Rs.), as of Mar 25, the value is 13.44. This value is within the healthy range. It has decreased from 13.94 (Mar 24) to 13.44, marking a decrease of 0.50.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 66.64. It has decreased from 80.56 (Mar 24) to 66.64, marking a decrease of 13.92.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 66.64. It has decreased from 80.56 (Mar 24) to 66.64, marking a decrease of 13.92.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 47.04. It has increased from 41.30 (Mar 24) to 47.04, marking an increase of 5.74.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 17.04. This value is within the healthy range. It has decreased from 18.37 (Mar 24) to 17.04, marking a decrease of 1.33.
- For PBIT / Share (Rs.), as of Mar 25, the value is 13.99. This value is within the healthy range. It has decreased from 16.23 (Mar 24) to 13.99, marking a decrease of 2.24.
- For PBT / Share (Rs.), as of Mar 25, the value is 13.51. This value is within the healthy range. It has decreased from 15.94 (Mar 24) to 13.51, marking a decrease of 2.43.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 10.40. This value is within the healthy range. It has decreased from 11.80 (Mar 24) to 10.40, marking a decrease of 1.40.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 10.52. This value is within the healthy range. It has decreased from 11.80 (Mar 24) to 10.52, marking a decrease of 1.28.
- For PBDIT Margin (%), as of Mar 25, the value is 36.21. This value is within the healthy range. It has decreased from 44.48 (Mar 24) to 36.21, marking a decrease of 8.27.
- For PBIT Margin (%), as of Mar 25, the value is 29.74. This value exceeds the healthy maximum of 20. It has decreased from 39.29 (Mar 24) to 29.74, marking a decrease of 9.55.
- For PBT Margin (%), as of Mar 25, the value is 28.71. This value is within the healthy range. It has decreased from 38.58 (Mar 24) to 28.71, marking a decrease of 9.87.
- For Net Profit Margin (%), as of Mar 25, the value is 22.10. This value exceeds the healthy maximum of 10. It has decreased from 28.56 (Mar 24) to 22.10, marking a decrease of 6.46.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 22.36. This value exceeds the healthy maximum of 20. It has decreased from 28.56 (Mar 24) to 22.36, marking a decrease of 6.20.
- For Return on Networth / Equity (%), as of Mar 25, the value is 15.78. This value is within the healthy range. It has increased from 14.64 (Mar 24) to 15.78, marking an increase of 1.14.
- For Return on Capital Employeed (%), as of Mar 25, the value is 13.36. This value is within the healthy range. It has decreased from 19.24 (Mar 24) to 13.36, marking a decrease of 5.88.
- For Return On Assets (%), as of Mar 25, the value is 8.83. This value is within the healthy range. It has decreased from 13.32 (Mar 24) to 8.83, marking a decrease of 4.49.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.04. This value is within the healthy range. It has increased from 0.01 (Mar 24) to 0.04, marking an increase of 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.45. It has decreased from 0.49 (Mar 24) to 0.45, marking a decrease of 0.04.
- For Current Ratio (X), as of Mar 25, the value is 2.43. This value is within the healthy range. It has decreased from 11.82 (Mar 24) to 2.43, marking a decrease of 9.39.
- For Quick Ratio (X), as of Mar 25, the value is 1.98. This value is within the healthy range. It has decreased from 9.65 (Mar 24) to 1.98, marking a decrease of 7.67.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 6.02. This value is within the healthy range. It has increased from 3.87 (Mar 24) to 6.02, marking an increase of 2.15.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 35.12. This value is within the healthy range. It has decreased from 62.77 (Mar 24) to 35.12, marking a decrease of 27.65.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 22.44. This value is within the healthy range. It has decreased from 41.30 (Mar 24) to 22.44, marking a decrease of 18.86.
- For Enterprise Value (Cr.), as of Mar 25, the value is 29,662.03. It has increased from 17,211.94 (Mar 24) to 29,662.03, marking an increase of 12,450.09.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 24.77. This value exceeds the healthy maximum of 3. It has increased from 16.37 (Mar 24) to 24.77, marking an increase of 8.40.
- For EV / EBITDA (X), as of Mar 25, the value is 68.38. This value exceeds the healthy maximum of 15. It has increased from 36.80 (Mar 24) to 68.38, marking an increase of 31.58.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 24.66. This value exceeds the healthy maximum of 3. It has increased from 16.38 (Mar 24) to 24.66, marking an increase of 8.28.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 17.40. This value exceeds the healthy maximum of 3. It has increased from 8.40 (Mar 24) to 17.40, marking an increase of 9.00.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 24.66. This value exceeds the healthy maximum of 3. It has increased from 16.38 (Mar 24) to 24.66, marking an increase of 8.28.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Cohance Lifesciences Ltd:
- Net Profit Margin: 22.1%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 13.36% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 15.78% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 22.44
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.98
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 49.2 (Industry average Stock P/E: 52.68)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.04
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 22.1%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 215 Atrium, C Wing, 8th Floor, Mumbai Maharashtra 400093 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Vivek Sharma | Executive Chairman |
| Dr. V Prasada Raju | Managing Director |
| Mr. Pankaj Patwari | Non Executive Director |
| Ms. Shweta Jalan | Non Executive Director |
| Mr. Vinod Padikkal | Non Executive Director |
| Mr. Vinod Rao | Independent Director |
| Mr. K G Ananthakrishnan | Independent Director |
| Mr. U B Pravin Rao | Independent Director |
| Ms. Matangi Gowrishankar | Independent Director |
| Mr. Jai Shankar Krishnan | Independent Director |
FAQ
What is the intrinsic value of Cohance Lifesciences Ltd?
Cohance Lifesciences Ltd's intrinsic value (as of 15 January 2026) is ₹504.77 which is 14.20% higher the current market price of ₹442.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹16,908 Cr. market cap, FY2025-2026 high/low of ₹1,328/439, reserves of ₹3,749 Cr, and liabilities of ₹5,568 Cr.
What is the Market Cap of Cohance Lifesciences Ltd?
The Market Cap of Cohance Lifesciences Ltd is 16,908 Cr..
What is the current Stock Price of Cohance Lifesciences Ltd as on 15 January 2026?
The current stock price of Cohance Lifesciences Ltd as on 15 January 2026 is ₹442.
What is the High / Low of Cohance Lifesciences Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Cohance Lifesciences Ltd stocks is ₹1,328/439.
What is the Stock P/E of Cohance Lifesciences Ltd?
The Stock P/E of Cohance Lifesciences Ltd is 49.2.
What is the Book Value of Cohance Lifesciences Ltd?
The Book Value of Cohance Lifesciences Ltd is 99.0.
What is the Dividend Yield of Cohance Lifesciences Ltd?
The Dividend Yield of Cohance Lifesciences Ltd is 0.00 %.
What is the ROCE of Cohance Lifesciences Ltd?
The ROCE of Cohance Lifesciences Ltd is 14.9 %.
What is the ROE of Cohance Lifesciences Ltd?
The ROE of Cohance Lifesciences Ltd is 12.7 %.
What is the Face Value of Cohance Lifesciences Ltd?
The Face Value of Cohance Lifesciences Ltd is 1.00.